Abdin, E, Chong, SA, Seow, E, et al. (2019) Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia. Quality of Life Research 28(1): 177–186.
Google Scholar | Crossref | Medline Adrianzén, C, Arango-Dávila, C, Araujo, DM, et al. (2010) Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: Post hoc analysis from a 3-year observational study. Human Psychopharmacology 25(6): 439–447.
Google Scholar | Crossref | Medline Arango, C, Adami, H, Sherr, JD, et al. (1999) Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. The American Journal of Psychiatry 156(7): 1097–1099.
Google Scholar | Medline Ascher-Svanum, H, Zhu, B, Faries, D, et al. (2008) Tardive dyskinesia and the 3-year course of schizophrenia: Results from a large, prospective, naturalistic study. The Journal of Clinical Psychiatry 69(10): 1580–1588.
Google Scholar | Crossref | Medline Barnes, TR (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 25(5): 567–620.
Google Scholar | SAGE Journals | ISI Bebbington, PE, Angermeyer, M, Azorin, JM, et al. (2009) Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta psychiatrica Scandinavica. Supplementum 438: 22–28.
Google Scholar | Crossref Bobes, J, Garcia-Portilla, MP, Bascaran, MT, et al. (2007) Quality of life in schizophrenic patients. Dialogues in Clinical Neuroscience 9(2): 215–226.
Google Scholar | Crossref | Medline Bohlega, SA, Al-Foghom, NB (2013) Drug-induced Parkinson’s disease. A clinical review. Neurosciences 18(3): 215–221.
Google Scholar Brazier, JE, Yang, Y, Tsuchiya, A, et al. (2010) A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics 11(2): 215–225.
Google Scholar | Crossref | Medline | ISI Briggs, A, Wild, D, Lees, M, et al. (2008) Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation. Health and Quality of Life Outcomes 6(1): 105.
Google Scholar | Crossref | Medline Browne, S, Roe, M, Lane, A, et al. (1996) Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica 94(2): 118–124.
Google Scholar | Crossref | Medline Carbon, M, Hsieh, C-H, Kane, JM, et al. (2017) Tardive Dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. The Journal of Clinical Psychiatry 78(3): e264–e278.
Google Scholar | Crossref | Medline Caroff, SN (2019) Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatric Disease and Treatment 15: 785–794.
Google Scholar | Crossref | Medline Chan, YH (2004) Biostatistics 201: Linear regression analysis. Singapore Medical Journal 45(2): 55–61.
Google Scholar | Medline Chong, SA, Tay, JA, Subramaniam, M, et al. (2009) Mortality rates among patients with schizophrenia and tardive dyskinesia. Journal of Clinical Psychopharmacology 29(1): 5–8.
Google Scholar | Crossref | Medline Chou, C-Y, Ma, M-C, Yang, T-T (2014) Determinants of subjective health-related quality of life (HRQoL) for patients with schizophrenia. Schizophrenia Research 154(1): 83–88.
Google Scholar | Crossref | Medline Constantine, RJ, Tandon, R (2007) Antipsychotics equivalent? CUtLASS renews the debate. Current Psychiatry 6(2): 8.
Google Scholar Cornett, EM, Novitch, M, Kaye, AD, et al. (2017) Medication-induced Tardive Dyskinesia: A review and update. The Ochsner Journal 17(2): 162–174.
Google Scholar | Medline Craig, BM, Rand, K (2018) Choice defines QALYs: A US valuation of the EQ-5D-5L. Medical Care 56(6): 529–536.
Google Scholar | Crossref | Medline D’Souza, RS, Hooten, WM (2020) Extrapyramidal Symptoms. Treasure Island, FL: StatPearls Publishing.
Google Scholar Emsley, R, Niehaus, DJ, Oosthuizen, PP, et al. (2011) Subjective awareness of tardive dyskinesia and insight in schizophrenia. European Psychiatry 26(5): 293–296.
Google Scholar | Crossref | Medline First, MB, Spitzer, RL, Gibbon, M, et al. (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometric Research, New York State Psychiatric Institute.
Google Scholar Gerlach, J (1981) Prevention/treatment of tardive dyskinesia. Acta psychiatrica Scandinavica. Supplementum 291: 117–128.
Google Scholar | Crossref | Medline Gervin, M, Barnes, TRE (2018) Assessment of drug-related movement disorders in schizophrenia. Advances in Psychiatric Treatment 6(5): 332–341.
Google Scholar | Crossref Halliday, J, Farrington, S, Macdonald, S, et al. (2002) Nithsdale Schizophrenia Surveys 23: Movement disorders. 20-year review. The British Journal of Psychiatry 181: 422–427.
Google Scholar | Crossref | Medline | ISI Hawley, C, Fineberg, N, Roberts, A, et al. (2003) The use of the Simpson Angus Scale for the assessment of movement disorder: A training guide. International Journal of Psychiatry in Clinical Practice 7(4): 349–2257.
Google Scholar | Crossref | Medline Herdman, M, Gudex, C, Lloyd, A, et al. (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research 20(10): 1727–1736.
Google Scholar | Crossref | Medline | ISI Hofer, A, Mizuno, Y, Wartelsteiner, F, et al. (2020) Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. European Psychiatry 46: 42–47.
Google Scholar | Crossref Huang, Y, Pan, L, Teng, F, et al. (2017) A cross-sectional study on the characteristics of Tardive Dyskinesia in patients with chronic schizophrenia. Shanghai Archives of Psychiatry 29(5): 295–303.
Google Scholar | Medline Jeste, DV, Caligiuri, MP, Paulsen, JS, et al. (1995) Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry 52(9): 756–765.
Google Scholar | Crossref | Medline Jones, PB, Barnes, TRE, Davies, L, et al. (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63(10): 1079–1087.
Google Scholar | Crossref | Medline Kay, SR, Fiszbein, A, Opler, LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13(2): 261–276.
Google Scholar | Crossref | Medline | ISI Kim, JH (2019) Multicollinearity and misleading statistical results. Korean Journal of Anesthesiology 72(6): 558–569.
Google Scholar | Crossref | Medline Kumsa, A, Agenagnew, L, Alemu, B, et al. (2020) Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic. PLoS ONE 15(7): e0235365.
Google Scholar | Crossref | Medline Larsen, EB, Gerlach, J (1996) Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatrica Scandinavica 93(5): 381–388.
Google Scholar | Crossref | Medline Lee, J, Jiang, J, Sim, K, et al. (2010) The prevalence of tardive dyskinesia in Chinese Singaporean patients with schizophrenia: Revisited. Journal of Clinical Psychopharmacology 30(3): 333–335.
Google Scholar | Crossref | Medline Lee, J, Jiang, J, Sim, K, et al. (2011) Gender differences in Singaporean Chinese patients with schizophrenia. Asian Journal of Psychiatry 4(1): 60–64.
Google Scholar | Crossref | Medline Lehman, AF, Lieberman, JA, Dixon, LB, et al. (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. The American Journal of Psychiatry 161(2 Suppl.): 1–56.
Google Scholar | Medline | ISI Leucht, S, Heres, S, Kissling, W, et al. (2013) Pharmacological treatment of schizophrenia. Fortschritte der Neurologie Psychiatrie 81(5): e1–e13.
Google Scholar | Crossref | Medline Lim, MWZ, Lee, J (2018) Determinants of health-related quality of life in schizophrenia: Beyond the medical model. Frontiers in Psychiatry 9: 712.
Google Scholar | Crossref | Medline Longworth, L, Yang, Y, Young, T, et al. (2014) Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment 18(9): 1–224.
Google Scholar | Crossref | Medline Luyten, J, Naci, H, Knapp, M (2016) Economic evaluation of mental health interventions: An introduction to cost-utility analysis. Evidence-Based Mental Health 19(2): 49–53.
Google Scholar | Crossref | Medline McEvoy, J, Gandhi, SK, Rizio, AA, et al. (2019) Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Quality of Life Research 28(12): 3303–3312.
Google Scholar | Crossref | Medline Macpherson, R, Collis, R (1992) Tardive dyskinesia. Patients’ lack of awareness of movement disorder. British Journal of Psychiatry 160: 110–112.
Google Scholar | Crossref | Medline Mamo, DC, Sweet, RA, Keshavan, MS (1999) Managing antipsychotic-induced parkinsonism. Drug Safety 20(3): 269–275.
Google Scholar | Crossref | Medline Meltzer, HY (2004) What’s atypical about atypical antipsychotic drugs? Current Opinion in Pharmacology 4(1): 53–57.
Google Scholar | Crossref | Medline Modestin, J, Stephan, PL, Erni, T, et al. (2000) Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophrenia Research 42(3): 223–230.
Google Scholar | Crossref | Medline Morgenstern, H, Glazer, WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry 50(9): 723–733.
Google Scholar | Crossref | Medline Patel, KR, Cherian, J, Gohil, K, et al. (2014) Schizophrenia: Overview and treatment options. Pharmacy and Therapeutics 39(9): 638–645.
Google Scholar Ponizovsky, AM, Grinshpoon, A, Levav, I, et al. (2003) Life satisfaction and suicidal attempts among persons with schizophrenia. Comprehensive Psychiatry 44(6): 442–447.
Google Scholar | Crossref | Medline | ISI Ritsner, M, Gibel, A, Perelroyzen, G, et al. (2004) Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: A naturalistic comparative study. Journal of Clinical Psychopharmacology 24(6): 582–591.
Google Scholar | Crossref | Medline Rush, AJ (2000) Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association.